Phase I study of doxorubicin, ICRF-187 and granulocyte/macrophage-colony-stimulating factor

A group of 16 patients with advanced malignancy were entered on a phase I trial of escalating doses of doxorubicin with ICRF-187 for cardioprotection and granulocyte/macrophage-colony-stimulating factor (GMCSF) for bone marrow protection. Patients received intravenous ICRF-187 (dose ratio 20:1 ICRF-187: doxorubicin) 30 min prior to doxorubicin. GMCSF at a dose of 15 μg kg^-1 day^-1 was self-administered subcutaneously on days 3-14 of the cycle. Doxorubicin was administered every 21 days. Substantial hematological and non-hematological toxicity was seen. Fever, malaise, and pulmonary symptoms, thought to be due to GMCSF, were not eliminated by reduction in the GMCSF dose to 10 or 5 μg kg^-1 day^-1. Severe hematological toxicity was seen despite GMCSF administration and it was not possible to escalate the doxorubicin dose above 72 mg/m² with this combination. Dose escalation of doxorubicin may be more feasible with the use of other growth factors or growth factor combinations.